Global Human Serum Albumin (HSA) Market to Generate $7,124.90 Million by 2031, Due to Increasing Awareness about Blood-Related Disorders

Human serum albumin, the most important and abundantly found protein in blood plasma, is responsible for transport of almost all the vital compounds found in the body, including hormones, fatty acids, etc. Human serum albumin is primarily produced in liver and is monomeric in nature. The ability of human serum albumin to bind drug molecules without introducing any toxicity in those molecules has made it quite popular in the pharmaceutical industry.

Forecast Analysis of the Human Serum Albumin (HSA) Market

In recent years, there has been an increase in the awareness about blood-related disorders such as anemia, hypovolemia, etc. which is expected to be the primary growth driver of the global human serum albumin (HSA) market in the forecast years. Along with this, a surge in the demand for medical demands and diagnostic procedures is expected to push the market further. Also, growing usage of human serum albumin in biopharmaceutical treatments is predicted to offer numerous investment and growth opportunities to the market in the analysis timeframe. However, strict government regulations in developing countries may restrain the growth of the human serum albumin (HSA) market in the forecast period.

Regionally, the human serum albumin (HSA) market in the Asia-Pacific region is expected to be the most dominant by 2031. The growing prevalence of chronic diseases related to blood and an increasing proportion of the aging population in this region are anticipated to become the main growth drivers of the market in this region.

According to the report published by Research Dive, the global human serum albumin (HSA) market is expected to gather a revenue of $7,124.90 million by 2031 and grow at 6.8% CAGR in the 2022-2031 timeframe. Some prominent market players include Grifols, S.A., Baxter, Kedrion S.p.A, CSL Behring, Octapharma Brasil Ltd., Thermo Fisher Scientific, Biotest, Bio Group Co., Ltd., Novozymes, Takeda Pharmaceutical Company Limited, and many others.

Covid-19 Impact on the Human Serum Albumin (HSA) Market

The outbreak of the Covid-19 pandemic has had a massive negative effect on almost all industries and businesses across the world. The human serum albumin (HSA) market, however, faced a moderate impact of the pandemic. Shutdown of human albumin production and distribution companies led to disruptions in global supply chains which affected the steady supply of human serum albumin. However, at the same time, there was a marked increase in research related to human serum albumin which helped in the growth of the market during the pandemic period.

Significant Market Developments

The significant companies operating in the industry are adopting numerous growth strategies & business tactics such as partnerships, collaborations, mergers & acquisitions, and launches to maintain a robust position in the overall market, thus helping the human serum albumin (HSA) market to flourish. For instance:

• In March 2021, Albumedix, a UK-based biotechnology company, announced that it was collaborating with FUJIFILM Wako Pure Chemical Corporation, a medical products manufacturing company. This collaboration is expected to offer numerous growth opportunities to both the companies, especially in the Chinese and Japanese markets.
   
• In August 2022, Sartorius, a laboratory instruments manufacturing company, announced the acquisition of Albumedix, a leading biotech firm. This acquisition is predicted to help Sartorius to expand its market share substantially in the coming period.